# Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age

> **NCT03143101** · PHASE4 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 200 (actual)

## Conditions studied

- Influenza
- Healthy

## Interventions

- **BIOLOGICAL:** FluMist trivalent (2015-2016)
- **BIOLOGICAL:** FluMist Quadrivalent (2015-2016)
- **BIOLOGICAL:** FluMist Quadrivalent (2017-2018)

## Key facts

- **NCT ID:** NCT03143101
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-08
- **Primary completion:** 2017-09-29
- **Final completion:** 2017-09-29
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2018-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03143101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03143101, "Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03143101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*